CACHEXIA

This early-phase trial tests a new drug called SXRN, made from DNA, in 28 people with advanced solid tumors who have run out of standard options. The main goals are to check safety and find the right dose, while also seeing if it helps with appetite and physical function. The stu…

This study tests a drug called ponsegromab combined with standard chemotherapy to see if it helps adults with advanced pancreatic cancer who are losing weight and appetite (cachexia). About 982 participants will receive either ponsegromab or a placebo alongside their first chemot…

This early-stage trial tests a new, easier-to-absorb version of megestrol acetate (a drug that stimulates appetite) in 5 women with advanced cervical cancer who are undergoing chemoradiation. The goal is to see if it helps them maintain weight and improve nutrition during treatme…

This early-stage trial tests AV-380, an antibody that blocks a protein linked to cancer-related weight loss (cachexia). About 30 adults with advanced solid tumors and high GDF-15 levels will receive AV-380 alongside their standard chemotherapy. The main goal is to check safety an…

This study is not testing a new drug or treatment. Instead, researchers want to make sure their lab tests and equipment give accurate and repeatable results when studying conditions like obesity, diabetes, heart disease, and bone loss. Up to 100 healthy volunteers and people with…

This study is looking for genetic differences that may explain why many people with pancreatic cancer develop severe muscle wasting (cachexia). Researchers will collect blood samples from 100 patients to analyze their DNA. The goal is to find markers that could lead to earlier de…

This study follows 200 people with cancers of the esophagus, stomach, pancreas, colon, or rectum who are scheduled for surgery, along with some healthy controls. Researchers will track weight, muscle mass, physical activity, quality of life, and immune markers over a year to bett…